Candidemia: Incidence rates, type of species, and risk factors at a tertiary care academic hospital in China

International Journal of Infectious Diseases

Volumn 22, Issue , 2014, Pages 4-8

  Wu, Zengbin ^a   Liu, Yingbin ^a   Feng, Xiaobo ^a   Liu, Ying ^a   Wang, Shuyun ^a   Zhu, Xiaodong ^a   Chen, Qiqi ^a   Pan, Shuming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Candid albicans; Candida guilliermondii; Candidemia; Incidence

Indexed keywords

ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDEMIA; CENTRAL VENOUS CATHETERIZATION; CHILD; CHINA; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFANT; INFECTION RISK; INTRAVENOUS FEEDING; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PICHIA GUILLIERMONDII; PREMATURE LABOR; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SURGERY; TERTIARY HEALTH CARE; VERY ELDERLY; YOUNG ADULT; CANDIDA; CANDIDIASIS; EPIDEMIOLOGY; MICROBIOLOGY; NEWBORN; PARENTERAL NUTRITION; PHYSIOLOGY; PREMATURITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNIVERSITY HOSPITAL;

CANDIDA; CANDIDA ALBICANS; CANDIDEMIA; CANDIDIASIS; CHINA; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; MALE; PARENTERAL NUTRITION; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY HEALTHCARE;

EID: 84896532742     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.11.011     Document Type: Article

References (19)

1. Macphail G., Taylor G., Buchanan-Chell M., Ross C., Wilson S., Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002, 45:141-145.
2. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000, 21:510-515.
3. Pfaller M.A., Jones R.N., Marshall S.A., Coffman S.L., Hollis R.J., Edmond M.B., et al. Inducible ampC beta-lactamase producing Gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997, 28:211.
4. Wu J.Q., Zhu L.P., Ou X., Xu B., Hu X.P., Wang X., et al. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011, 49:552-555.
5. Yapar N., Pullukcu H., Avkan-Oguz V., Sayin-Kutlu S., Ertugrul B., Sacar S., et al. Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Med Mycol 2011, 49:26-31.
6. Barchiesi F., Spreghini E., Tomassetti S., Della Vittori A., Arzeni D., Manso E., et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006, 50:2719-2727.
7. Borg-von Z.M., Kunz L., Rüchel R., Reichard U., Weig M., Groß U. Epidemiology and antifungal susceptibilities of Candida spp to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007, 60:424-428.
8. Desnos-Ollivier M., Ragon M., Robert V., Raoux D., Gantier J.C., Dromer F. Debaryomyces hansenii (Candida famata), a rare human fungal pathogen often misidentified as Pichia guilliermondii (Candida guilliermondii). J Clin Microbiol 2008, 46:3237-3242.
9. Passos X.S., Sales W.S., Maciel P.J., Costa C.R., Miranda K.C., Lemos J.A., et al. Candida colonization in intensive care unit patients' urine. Mem Inst Oswaldo Cruz 2005, 100:925-928.
10. Savini V., Catavitello C., Di Marzio I., Masciarelli G., Astolfi D., Balbinot A., et al. Pan-azole-resistant Candida guilliermondii from a leukemia patient's silent funguria. Mycopathologia 2010, 169:457-459.
11. Ma X., Sun W., Liu T. [Clinical characteristics of Candida septicemia seen in a neonatal intensive care unit: analysis of 9 cases]. Zhonghua Er Ke Za Zhi 2006, 44:694.
12. Beyda N.D., Lewis R.E., Garey K.W. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother 2012, 46:1086-1096.
13. Kibbler C. Fungaemia and disseminated fungal infection. Principles and practice of clinical mycology 1996, John Wiley & Sons Ltd.
14. Lo S.M., Yu Y.M., Lee L.Y., Wong M.L., Chair S.Y., Kalinowski E.J., et al. Overview of the Shenzhen emergency medical service call pattern. World J Emerg Med 2012, 3:251-256.
15. Pfaller M., Jones R., Doern G., Fluit A., Verhoef J., Sader H., et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999, 35:19.
16. Singh-Babak S.D., Babak T., Diezmann S., Hill J.A., Xie J.L., Chen Y.L., et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog 2012, 8:e1002718.
17. Savini V., Catavitello C., Onofrillo D., Masciarelli G., Astolfi D., Balbinot A., et al. What do we know about Candida guilliermondii?. A voyage throughout past and current literature about this emerging yeast. Mycoses 2011, 54:434-441.
18. Ge X., Cavallazzi R., Li C., Pan S.M., Wang Y.W., Wang F.L. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev 2012, 14:3.
19. Hamilton H.C., Foxcroft D. Central venous access sites for the prevention of venous thrombosis, stenosis, and infection in patients requiring long-term intravenous therapy. Anesth Analg 2008, 106. 345-345.